{"id":545,"date":"2022-08-11T20:06:24","date_gmt":"2022-08-11T20:06:24","guid":{"rendered":"https:\/\/medicalmarijuanainc.com\/?p=1013717"},"modified":"2022-08-11T20:06:24","modified_gmt":"2022-08-11T20:06:24","slug":"medical-marijuana-inc-subsidiary-hm-pharma-submits-cbd-product-dossier-receives-sanitary-registration-in-brazil","status":"publish","type":"post","link":"https:\/\/medicalmarijuanainc.com\/2022\/08\/11\/medical-marijuana-inc-subsidiary-hm-pharma-submits-cbd-product-dossier-receives-sanitary-registration-in-brazil\/","title":{"rendered":"Medical Marijuana, Inc. Subsidiary HM Pharma Submits CBD Product Dossier; Receives Sanitary Registration in Brazil"},"content":{"rendered":"
SAN DIEGO, CA, Aug. 11, 2022 (GLOBE NEWSWIRE) — via\u00a0NewMediaWire<\/a>\u00a0\u2013\u00a0Medical Marijuana, Inc.<\/a>\u00a0(OTC: MJNA) (the \u201cCompany\u201d), the first-ever publicly traded cannabis company in the United States that launched the world\u2019s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today its pharmaceutical subsidiary,\u00a0HM Pharma<\/a>, has submitted a product dossier for its cannabidiol (CBD) products after receiving Sanitary Authorization from ANVISA, Brazil\u2019s Health Regulatory Agency.<\/p>\n Under ANVISA Normative 327\/2019, this registration allows companies such as HM Pharma to bulk import raw extracts, isolated cannabinoids or finished products as well as manufacture and distribute cannabis products to pharmacies in Brazil.<\/p>\n \u201cThis is a large accomplishment for our company and great news for the citizens of Brazil,\u201d said Matheus Patelli, Managing Director of HM Pharma. \u201cSubmitting our dossier is the final step to registering our product as a pharmaceutical product in Brazil enabling our company to sell our products in pharmacies. We hope to provide another option to access CBD for those in need.\u201d<\/p>\n Medical Marijuana, Inc. subsidiary HempMeds\u00ae Brasil was the first company to legally import products to Brazil in 2015 utilizing Brazil\u2019s Compassionate Use laws. The compassionate use market in Brazil is thriving and it will continue to coexist with the medical market. HempMeds\u00ae Brasil, which is currently growing 75% faster than the overall Brazilian CBD market, and is the leading company in Brazil’s cannabis industry, will continue to operate under the compassionate use model, while HM Pharma will operate under ANVISA Normative 327\/2019.<\/p>\n \u201cIt\u2019s tremendous to see continued growth and regulatory progress for our company in Brazil,\u201d said Medical Marijuana, Inc. CEO Blake Schroeder. \u201cWe are optimistic about our incredible forward momentum into the pharmaceutical space, and we look forward to sharing more exciting updates on our new sales channels in the near future.\u201d<\/p>\n About Medical Marijuana, Inc.<\/b><\/p>\n We are a company of firsts\u00ae<\/a>. Medical Marijuana, Inc. (MJNA<\/a>) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by\u00a0Kannaway\u00ae<\/a>\u00a0and\u00a0HempMeds\u00ae<\/a>; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including\u00a0AXIM\u00ae Biotechnologies, Inc<\/a>.<\/a>\u00a0and\u00a0Neuropathix<\/a>. Medical Marijuana, Inc. was named a top CBD producer by\u00a0CNBC<\/a>. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product\u00a0Real Scientific Hemp Oil<\/a>\u00a0has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.<\/p>\n Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at\u00a0OTCMarkets.com<\/a>\u00a0or by visitingwww.medicalmarijuanainc.com<\/a>. To see Medical Marijuana, Inc.’s corporate video,\u00a0click here<\/a>.<\/p>\n FORWARD-LOOKING DISCLAIMER<\/b><\/p>\n This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and\/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.<\/p>\n FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE<\/b><\/p>\n These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.<\/p>\n LEGAL DISCLOSURE<\/b><\/p>\n Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.<\/p>\n CONTACT:<\/b>
\nPublic Relations Contact:
\nKyle Porter
\nCMW Media
\nP. 858-221-8001
\nkyle@cmwmedia.com
\n<\/a>www.cmwmedia.com<\/p>\n